Company > About CARMAT > Project


The total artificial heart which reproduces the shape and all of the essential functions of the human heart as closely as possible

CARMAT is developing this orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system.

The objective is to meet a world-wide public healthcare need, that is to say the treatment of advanced heart failure which is the result of numerous cardiovascular illnesses, such as coronary diseases and arterial hypertension.
It is estimated that over 20 million people1  are suffering from heart failure in Europe and in the US2, 3.  It is the only cardiovascular illness which is on the rise despite therapeutic progress, particularly in the management of acute myocardial infarction.
It often has a poor outcome: more than 40% of patients die within a year of their first hospitalisation4.

Cardiologists and cardiac surgeons only have one possible treatment for patients suffering from advanced end-stage heart failure: heart transplantation. Unfortunately, this cannot meet all needs, since the number of transplants is very insufficient and the operation presents many contra-indications (arterial hypertension, spreading cancer, etc.).

The CARMAT heart is designed for patients suffering from:

Chronic terminal heart failure reaching class IV on the New York Heart Association classification; or acute terminal heart failure following a massive myocardial infarction.

The main aim of the biocompatible heart developed by CARMAT is to offer a reliable new treatment and innovative therapeutic solution to heart failure patients who are not eligible for a transplant and who have exhausted every drug-related possibility.

It should allow these patients, for whom no treatment is available and who are currently treated in hospital at very high cost to the community, to return home and even enjoy an active life once more.

This solution will be implemented at costs lower than* or comparable to those for cardiac transplants.
*The price of the CARMAT total artificial heart should stand at between EUR 140,000 and 180,000.

A team dedicated to developing a totally implantable heart as close as possible to the human heart

  1. Surgical option for the management of congestive heart failure - Cardiology (2004)
  2. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008.  European Heart Journal (2008) 29, 2388–2442
  3. 2 Heart Disease and Stroke Statistics — 2010 Update, American Heart Association
  4. Stewart S, et al. More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315–322.